Melane Sampson, Author at BioTuesdays

Markets

Canaccord ups Neuronetics PT to $20 from $8

Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared...

January 19, 2021

Executive Moves

Justin Zelin joins BTIG as biotech analyst

Justin Zelin BTIG has expanded its healthcare research coverage, adding Justin Zelin to its research and strategy division as a director. His biotech research coverage will include cell therapy, targeted oncology...

January 15, 2021

Developments

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

Diabeloop and SFC Fluidics agreed to develop a Type 1 diabetes system that integrates SFC’s alternate controller-enabled (ACE) insulin pod into Diabeloop’s automated insulin delivery solution in the U.S. The new...

January 11, 2021

Developments

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Closely held Soricimed Biopharma and Orano Med, a nuclear biotech company based in Piano, TX entered an agreement to develop a novel peptide receptor radionuclide therapy (PRRT) to treat solid tumor cancers. The...

January 7, 2021

Developments

Profound Medical Q4 preliminary revenue beats consensus estimates

Profound Medical (NASDAQ:PROF; TSX:PRN) preliminary revenue for the fourth quarter of 2020 of $3.7-million beat the Street estimate of $2.7-million, despite the pandemic surge. “We believe strong TULSA-PRO adoption and...

January 6, 2021

Markets

BTIG starts Delcath Systems at buy; PT $23

BTIG initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and price target of $23. The stock closed at $16.91 on Jan. 4. Delcath has developed HEPZATO, a percutaneous hepatic perfusion system that “we...

January 5, 2021

Developments

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

An independent data safety monitoring board (DSMB) has approved continuation of Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a AMBITION clinical trial for the treatment of advanced non-alcoholic steatohepatitis (NASH)...

December 29, 2020

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Markets

HCW starts Alpine Immune Sciences at buy; PT $21

H.C. Wainwright launched coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a “buy” rating and $21 price target. The stock finished at $14.57 on Dec. 18. Alpine is leading the way in developing protein-based...

December 21, 2020

Markets

Maxim starts Cyclo Therapeutics at buy; PT $12

Maxim Group initiated coverage of Cyclo Therapeutics (NASDAQ:CYTH) with a “buy” rating and $12 price target. The stock closed at $3.85 on Dec. 16. Cyclo is developing a Phase 3-ready hydroxypropyl beta cyclodextrin...

December 17, 2020

Author - Melane Sampson

Canaccord ups Neuronetics PT to $20 from $8

Justin Zelin joins BTIG as biotech analyst

Diabeloop, SFC Fluidics in U.S. development pact for Type 1 diabetes

Soricimed Biopharma, Orano Med in radiotherapeutics pact to treat solid tumors

Profound Medical Q4 preliminary revenue beats consensus estimates

BTIG starts Delcath Systems at buy; PT $23

DSMB recommends continuation of Hepion Pharma Phase 2a AMBITION trial in NASH

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

HCW starts Alpine Immune Sciences at buy; PT $21

Maxim starts Cyclo Therapeutics at buy; PT $12

Subscribe